The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Thromboxane synthase inhibition enhances furosemide-induced renal vasodilation.

The effects of furegrelate (a thromboxane synthase inhibitor), indomethacin, and the combination on urine volume (V), para-aminohippurate clearance (CPAH), and mean arterial pressure (MAP) before and after intravenous furosemide were examined in Sprague-Dawley rats. Prior to furosemide, none of the treatments changed MAP, V, or CPAH. Furosemide increased urine volume from 16 +/- 7 to 148 +/- 25 microL.min-1. Concomitant administration of furegrelate or indomethacin did not affect furosemide-induced diuresis, but the combination of indomethacin, furegrelate, and furosemide caused increased diuresis (to 254 +/- 40 microliters.min-1, p < 0.05, compared with furosemide alone). Furosemide alone or with the other drugs had no effect on mean arterial pressure. CPAH was increased from 3.0 +/- 0.4 to 4.6 +/- 0.8 ml.min-1.100g-1 (p < 0.05, n = 6) by furosemide, and to an even greater extent (6.7 +/- 0.8, n = 6) after pretreatment with furegrelate. Pretreatment with indomethacin alone or in combination with furegrelate abolished the furosemide-induced CPAH increment. Urine excretion of the prostacyclin hydrolysis product 6-ketoprostaglandin F1 alpha was increased by furosemide in the presence of furegrelate. Given that the transient renal vasodilation with furosemide is due to prostanoid precursor release, these results are consistent with redirection of arachidonate metabolism toward vasodilator prostaglandins by furegrelate.[1]


  1. Thromboxane synthase inhibition enhances furosemide-induced renal vasodilation. Wilson, T.W., Badahman, A.H., Kaushal, R.D. Clinical and investigative medicine. Médecine clinique et experimentale. (1993) [Pubmed]
WikiGenes - Universities